Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PEG 400 in Healthy Males
NCT02260076Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2001
- Primary completion
- Mar 2002
- Modality
- Polymer-based Nanoparticles
01
Overview
Phase 1, randomised, double-blind trial comparing PEG 400 with Placebo (2 arms). Primary endpoints: Clinically relevant findings in vital signs, Clinically relevant findings in laboratory tests and 4 more. Started Sep 2001; status: completed.
02
Drugs
polyethylene glycol 400
Beyond the preview
Go deeper on NCT02260076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260076.